alpha-1,3-galactosyltransferase-expressing allogeneic lung tumor cell vaccine

{
  "id": "MLC-T-ONC-009977",
  "term": "alpha-1,3-galactosyltransferase-expressing allogeneic lung tumor cell vaccine",
  "field": "Oncology and biomedicine",
  "definition": "An allogeneic lung cancer vaccine with potential immunostimulating and antineoplastic activities. Derived from allogeneic lung tumor cells, alpha-1,3-galactosyltransferase-expressing allogeneic lung tumor cell vaccine is engineered to express the murine alpha-1,3-galactosyltransferase (GalT), an enzyme humans lack. GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes in glycoproteins and in glycolipids on the cell membranes of the allogeneic lung tumor cells present in the vaccine, essentially producing a \"xenograft\". The hyperacute rejection involves pre-existing human anti-alpha-gal antibodies that bind the foreign alpha-gal epitopes expressed by the vaccine tumor cell “xenograft”, resulting in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous lung tumor cells with unmodified carbohydrate epitopes.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/alpha-13-galactosyltransferase-expressing-allogeneic-lung-tumor-cell-vaccine/"
}